Amphastar Pharmaceuticals has built a vertically integrated platform focusing on technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceuticals. Despite steady revenue growth through 2024, top-line slipped slightly in 2025 due to product mix and competitive factors. Operating income and net income declined more noticeably, reflecting increased R&D spend and commercial integration costs following acquisitions like BAQSIMI®. The company’s expansion into biosimilars and proprietary pipelines positions it for future growth, but regulatory hurdles and supply chain risks remain key uncertainties. Amphastar maintains a solid liquidity base with consistent free cash flow generation, alongside active share repurchases.